TLR4 and neoplasm: In addition, targeting TLR4 signaling with a TLR4 inhibitor (TAK‐242) reduced the number of infiltrating macrophages and decreased the levels of Inflammatory cytokines in the colon, leading to long‐term effects on tumor growth, which can be beneficial for CRC patients.240